"By January of this year, global vaccine reserves had run out. Any new outbreak of cholera will put additional strain on the current fragile ecosystem of vaccine production," the article says. The authors draw attention to the fact that, against the background of a shortage of drug stocks, active cholera outbreaks continue in 23 countries.

"Cholera threatens the lives of more than 1 billion people, but pharmaceutical companies do not deal with cholera vaccines due to their low profitability, because the poorest people suffer from this disease," the article explains. - The lack of capacity to produce cholera vaccines limits our ability to respond to outbreaks and conduct prevention campaigns. Increasing global production of cholera vaccines remains an important task in the medium and long term. Zambia currently expects to produce vaccines in volumes that will protect at least 2.4 million people at risk of cholera infection in the country."

The article notes that such extreme measures as suspending the standard two-dose vaccination regimen and switching to a single-dose regimen in order to maximize the use of remaining vaccine stocks did not help overcome the critical situation. The authors conclude that, against the background of the trend towards an increase in the number of outbreaks of the disease, investments in creating opportunities for the production of cholera vaccines at the local level are becoming "a critical element in the fight against this disease."

"The global community should provide the necessary support by investing in the creation of production facilities and guaranteeing orders for the supply of vaccines," the experts emphasize.